Q1 2025 Management View Kevin McNamara, CEO of Chemed, highlighted robust performance in VITAS operations, with a 7.3% year-over-year increase in admissions to 18,139 and a 13.1% growth in average ...

Epigenetic reprogramming holds promise for reversing aging, addressing cellular aging mechanisms and paving the way for innovative therapeutic strategies.